Improving cytotoxic properties of ferrocenes by incorporation of saturated N-heterocycles

High-efficiency Hg(II) adsorbent: FeS loaded on a carbon black from pyrolysis of waste tires and sequential reutilization as a photocatalyst

Iron-sulfur nano compounds have been proven to be effective in mercury removal, but the agglomeration, poor dispersion and mobility, and easy oxidation challenges limit their application. Herein, carbon black originating from pyrolysis of waste tires was used as a carrier of nano-FeS to obtain an efficient adsorbent (C@PDA-FeS). It is found that the C@PDA-FeS shows outstanding adsorption ability, excellent selectivity, and high removal rate. A maximum adsorption capacity of 1754 mg/g is obtained, and the residual Hg(II) ion concentration is as low as 3.2 μg/L in the simulated industrial wastewater, which meets the industrial discharge standard under the optimal conditions. Meanwhile, the removal rate of Hg(II) ion can reach 99.8% after up to 10 cycles. More importantly, the C@PDA-FeS still shows good adsorption efficiency, and the removal rate of Hg(II) ion is over 99% (25 mg/L Hg(II) concentration) after 90 days of storage, demonstrating the long-term stability and promising future of the adsorbent. In addition, the waste adsorbent (C@PDA-FeS/HgS) is reused as a photocatalyst to degrade methylene blue, and the corresponding degradation rate is 92.9% (10 mg/L).

Organometallic compounds in drug discovery: Past, present and future

In this review, we present an overview of some of the medicinally-relevant organometallic drugs that have been used in the past or that are currently in clinical trials as well as an example of compounds that are currently in the initial stage of drug development. Three main classes of organometallic complexes have been chosen for discussion: antimicrobial organoarsenicals, antimalarial and anticancer ferrocene-containing compounds and anticancer catalytic organometallic complexes. The purpose of this review is to provide readers with a focus on the significant progress that has been made for each of these respective fields of medicine.

The Cytotoxic Effect of Newly Synthesized Ferrocenes against Cervical Carcinoma Cells Alone and in Combination with Radiotherapy

Cervical cancer is one of the most common types of cancer in women, with approximately 500,000 new cases and 250,000 deaths every year. Radiotherapy combined with chemotherapy represents the treatment of choice for advanced cervical carcinomas. The role of the chemotherapy is to increase the sensitivity of the cancer cells to irradiation. Cisplatin, the most commonly used drug for this purpose, has its limitations. Thus, we used a family of ferrocene derivatives (in addition, one new species was prepared using standard Schlenk techniques) and studied their effects on cervical cancer cells alone and in combination with irradiation. We applied colorimetric assay to determine the cytotoxicity of the compounds; flow cytometry to analyze the production of reactive oxygen species (ROS), cell cycle, and mitochondrial membrane potential (MMP); immunochemistry to study protein expression; and colony forming assay to evaluate changes in radiosensitivity. Treatment with ferrocenes exhibited significant cytotoxicity against cervical cancer cells, associated with increasing ROS production and MMP changes, suggesting the induction of apoptosis. The combined activity of ferrocenes and ionizing radiation highlighted ferrocenes as potential radiosensitizing drugs, while their higher single-agent toxicity in comparison with routinely used cisplatin could also be promising. Our results demonstrate antitumor activity of several tested ferrocenes both alone and in combination with radiotherapy.

Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships

Cancer is one of the most fatal threatens to human health throughout the world. The major challenges in the control and eradication of cancers are the continuous emergency of drug-resistant cancer and the low specificity of anticancer agents, creating an urgent need to develop novel anticancer agents. Organometallic compounds especially ferrocene derivatives possess remarkable structural and mechanistic diversity, inherent stability towards air, heat and light, low toxicity, low cost, reversible redox, ligand exchange, and catalytic properties, making them promising drug candidates for cancer therapy. Ferrocifen, a ferrocene-phenol hybrid, has demonstrated promising anticancer properties on drug-resistant cancers. Currently, Ferrocifen is in pre-clinical trial against cancers. Obviously, ferrocene moiety is a useful template for the development of novel anticancer agents. This review will provide an overview of ferrocene-containing hybrids with potential application in the treatment of cancers covering articles published between 2010 and 2020. The mechanisms of action, the critical aspects of design and structure-activity relationships are also discussed.